Recently, we showed that SpiD3 exhibited potent preclinical anti-leukemic effects, exerting multifactorial CLL cytotoxicity through diminished NF-κB signaling and protein translation [40]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.